These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
939 related articles for article (PubMed ID: 27535135)
41. Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children. Cordioli MI; Moraes L; Bastos AU; Besson P; Alves MT; Delcelo R; Monte O; Longui C; Cury AN; Cerutti JM Thyroid; 2017 Feb; 27(2):182-188. PubMed ID: 27849443 [TBL] [Abstract][Full Text] [Related]
42. Occurrence of medullary thyroid carcinoma, bronchial carcinoid tumor, and papillary thyroid carcinoma in a family bearing the RET G691S polymorphism. Rotondi M; Ercolino T; Fonte R; Lagonigro MS; Leporati P; Villani L; La Manna L; Mannelli M; Chiovato L J Endocrinol Invest; 2009 Feb; 32(2):115-8. PubMed ID: 19411807 [TBL] [Abstract][Full Text] [Related]
43. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240 [TBL] [Abstract][Full Text] [Related]
44. Concurrent lymph node metastases of medullary and papillary thyroid carcinoma in a case with RET oncogene germline mutation. Papi G; Corrado S; Pomponi MG; Carapezzi C; Cesinaro A; LiVolsi VA Endocr Pathol; 2003; 14(3):269-76. PubMed ID: 14586073 [TBL] [Abstract][Full Text] [Related]
45. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Romei C; Ciampi R; Elisei R Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437 [TBL] [Abstract][Full Text] [Related]
46. A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer. Romei C; Elisei R Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572167 [TBL] [Abstract][Full Text] [Related]
47. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal. Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668 [TBL] [Abstract][Full Text] [Related]
48. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot. Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983 [TBL] [Abstract][Full Text] [Related]
49. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268 [TBL] [Abstract][Full Text] [Related]
50. Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer. Tobiás B; Halászlaki C; Balla B; Kósa JP; Árvai K; Horváth P; Takács I; Nagy Z; Horváth E; Horányi J; Járay B; Székely E; Székely T; Győri G; Putz Z; Dank M; Valkusz Z; Vasas B; Iványi B; Lakatos P Pathol Oncol Res; 2016 Jan; 22(1):27-33. PubMed ID: 26259532 [TBL] [Abstract][Full Text] [Related]
51. Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries. Vuong HG; Kondo T; Oishi N; Nakazawa T; Mochizuki K; Inoue T; Tahara I; Kasai K; Hirokawa M; Tran TM; Katoh R Cancer Med; 2016 Aug; 5(8):1883-9. PubMed ID: 27264674 [TBL] [Abstract][Full Text] [Related]
52. Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer. Rossi M; Buratto M; Tagliati F; Rossi R; Lupo S; Trasforini G; Lanza G; Franceschetti P; Bruni S; Degli Uberti E; Zatelli MC Thyroid; 2015 Feb; 25(2):221-8. PubMed ID: 25333496 [TBL] [Abstract][Full Text] [Related]
53. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036 [TBL] [Abstract][Full Text] [Related]
54. Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population. Gertz RJ; Nikiforov Y; Rehrauer W; McDaniel L; Lloyd RV Arch Pathol Lab Med; 2016 Feb; 140(2):134-9. PubMed ID: 26910217 [TBL] [Abstract][Full Text] [Related]
56. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Henderson YC; Shellenberger TD; Williams MD; El-Naggar AK; Fredrick MJ; Cieply KM; Clayman GL Clin Cancer Res; 2009 Jan; 15(2):485-91. PubMed ID: 19147753 [TBL] [Abstract][Full Text] [Related]
57. The prevalence of somatic RAS mutations in medullary thyroid cancer - a Polish population study. Oczko-Wojciechowska M; Pfeifer A; Rusinek D; Pawlaczek A; Zebracka-Gala J; Kowalska M; Kowal M; Swierniak M; Krajewska J; Gawlik T; Chmielik E; Czarniecka A; Szpak-Ulczok S; Jarząb B Endokrynol Pol; 2015; 66(2):121-5. PubMed ID: 25931041 [TBL] [Abstract][Full Text] [Related]